Androgen ablation is thought to exert selective pressure for the development of androgenindependent forms of prostate cancer. This study was set up to investigate the effects of surgical castration on the development of prostate adenocarcinoma (ADC) from its precursor (high-grade prostate intraepithelial neoplasia (HGPIN)) and on the occurrence of androgen-independent, poorly differentiated carcinoma (PDC) in (C57Bl/6 transgenic adenocarcinoma of mouse prostate) TRAMP mice. It was found that castration cures HGPIN and ADC and prevents their further occurrence and growth, but has no effect on PDC. This indicates that in this model, PDC is not the progression of ADC favoured by androgen ablation and that its initiating cells are different from those of HGPIN and ADC.
Introduction
Prostate cancer (PC) is particularly suitable for chemoprevention, as it is a common, slowly growing tumour with known histological precursors and a long subclinical phase, while its frequency increases with age. Extensive chemoprevention studies have thus been conducted on subjects mainly at risk on account of their age, and the results of some clinical trials have been published. PC is nearly always associated with a welldefined histological precursor, namely high-grade prostate intraepithelial neoplasia (HGPIN), 1 although this may also be found in the absence of cancer (true isolated HGPIN). The observation of HGPIN thus poses a clinical challenge, as it may very well herald the subsequent development of PC, whereas its treatment is fraught with uncertainty. Prostate-specific antigen evaluation and ultrasound surveillance are usually adopted, together with repeated prostate biopsies, in patients with isolated HGPIN.
Prostatectomy specimens show that androgen deprivation decreases the incidence and modifies the morphology of HGPIN in the function of the preoperative treatment duration, 2, 3 whereas oestrogen receptor modulators even seem to be able to eradicate it. 4 Antiandrogens are commonly used to treat isolated HGPIN, especially after the first cancer-negative biopsy and during the period when other biopsies are taken. Cyproterone acetate, 5 flutamide 6, 7 and bicalutamide 8, 9 reduce or delay the occurrence of PC in patients with isolated HGPIN.
Some mutant animals are particularly prone to develop HGPIN and various subtypes of cancer. In vivo studies are thus used to assess the efficacy of PC treatments and its precursor. Vitamin D and nonsteroidal anti-inflammatory drugs, for example, inhibit the formation or induce a regression of HGPIN in Nkx3.1 mice 10 and in C57Bl/6 transgenic adenocarcinoma of mouse prostate (TRAMP) mice. [11] [12] [13] The TRAMP model has been elaborated and extensively studied by Greenberg and his co-workers. [14] [15] [16] [17] These animals thus provide a useful model for the evaluation of treatments designed to decrease the growth and progression of PC. 18 The SV40Tag transgene under the probasin promoter (Probasin-Simian virus 40 T antigen) induces the development of HGPIN in all these mice from the 7th to 8th week of age, followed by well and moderately differentiated adenocarcinoma (ADC) and death from the 39th to 50th week. In 40-45% of cases, a substantial poorly differentiated small-cell carcinoma (PDC) component develops and causes death, usually as the result of widespread dissemination, at about 30 weeks. 19 The morphological analyses performed in this study have indicated that in TRAMP mice, PDC is not the evolution of ADC, but arises as an independent tumour that is poorly differentiated from the start and completely similar to human small-cell prostate smallcell carcinoma. 20 We have therefore assessed both the therapeutic effect of surgical castration on HGPIN and ADC in TRAMP mice, and its effect on the onset and growth of PDC and metastasis.
Materials and methods

Transgenic animals
Male and female TRAMP mice heterozygous for the PB-Tag transgene ( Jackson Laboratories, Bar Harbor, ME, USA) were crossed to obtain homozygous males in a pure C57BL/6 background. The presence of the transgene was confirmed by PCR. A total of 50 mice from synchronous litters were randomly divided into groups of 10 (groups A, B, C, D and E). At the 13th week of life, mice in group A were killed. Their genitourinary (GU) apparatus was removed and treated as indicated below. Mice in groups B and C were castrated according to the Greenberg Laboratory method available at: http://www.thegreenberglab.fhcrc.org/research/research_tramp_video1 and http://www.thegreenberglab. fhcrc.org/research/research_tramp_video2. Mice in groups D and E were sham-operated in the same way without the removal of the testicles. Mice in groups B and D were killed 7 weeks later, and mice in groups C and E were killed 17 weeks later (that is, at the 20th and 30th weeks of life, respectively (Table 1) . Mice were treated in accordance with the European Community guidelines. Macroscopic and microscopic analyses of the GU apparatus were performed at each killing.
Preparation of tissues
Four animals from each group received 50 mg kg 5-BrdU (5-bromo-2-deoxyuridine; Sigma-Aldrich, Oslo, Norway) intraperitoneally for 2 h before killing to mark cells dividing and synthesizing their DNA. Their organs and tissue samples were fixed in MetaCarnoy, the recommended fixative for BrdU immune labelling. 21 Those from the remaining six animals were fixed in 10% formalin. All 50 animals were autopsied and their organs searched for metastases. The GU apparatus was weighed without the testicles in the sham-operated controls and without the visible PDCs in all the animals. These tumour masses were measured, and their volume calculated from the major and minor diameters according to the formula: major diameter Â minor diameter 2 /minor diameter. Histological specimens were taken from the prostate, bladder, periaortic lymph nodes, kidneys with the adrenals, liver and lungs. To optimize the detection of microscopic metastases and ensure systematic uniform and random sampling, lungs were cut transversely to the trachea into 2.0-mm-thick parallel slabs with a random position of the first cut in the first 2.0 mm of the lung, resulting in 5-8 slabs per lung. The slabs were then embedded cut surface down.
Histology and immunohistochemistry
The histological specimens were embedded in paraffin, sectioned (2.5-4 mm slices) and stained with haematoxylin-eosin (H&E). Immunohistochemistry was performed with the following antibodies: anti-SV40Tag (Clone Pab 101; BD Pharmingen, San Jose, CA, USA) to reveal expression of the transforming transgene, antiproliferating cell nuclear antigen (PCNA, clone Pc10; Dako, Glostrup, Denmark); anti-androgen receptor (AR, clone PG-21; Upstate, Millipore's Bioscience Division, Billerica, ME, USA), anti-5-BrdU (clone MAB 5222; Chemicon, Billerica, ME, Millipore's Bioscience Division, USA), anti-synaptophysin (clone YE269; Abcam, Cambridge Science Park, Cambridge, UK) and anticytocheratin 8/18 (Progen Biotechnik GmbH, Heidelberg, Germany). The sections were then rinsed and incubated with the appropriate biotinylated secondary antibody and the alkaline avidin-biotin-phosphatase complex (Vector Laboratories, Burlingame, CA, USA).
Histopathological evaluation of tissues
The histological and immunohistochemical preparations were independently examined by four pathologists (RM, PM, TP and MI). The presence of normal tissue, HGPIN, ADC and PDC was evaluated according to the classification of mouse prostate lesions adopted by Kaplan-Lefko et al. 19 The percentage of prostate tissue area with normal and pathological aspects was scored and averaged for all groups. For quantitative evaluation of the immunohistochemical stainings for the nuclear antigens (SV40Tag, PCNA, BrdU and AR), the fraction of positive nuclei was expressed as a percentage of the total. For the evaluation of tissue structure, images of the histological sections were acquired with a Leica DC500 camera. Three to five images at original magnification Â 50 from each section were analyzed with the Adobe Photoshop program. The Lasso tool was used to delimit the surface occupied by the various tissue aspects and their areas were determined in pixels. The numerical values were entered on an Excel sheet. The total area of the prostate was evaluated. Those of its principal histological components (epithelial cells and stroma) were estimated as percentages. Groups were compared with a non-parametric test (Mann-Whitney test) with Po0.05 as the significance cutoff.
Statistical analysis
Data are presented as the mean ± s.e. and compared between groups using the two-tailed t-test or, when specified, with the Mann-Whitney test.
Results
TRAMP prostate carcinogenesis
Macroscopic and microscopic analyses of the GU apparatus of TRAMP mice were performed at 13, 20 and 30 weeks of age. At 13 weeks, the control (group A) GU weight was 0.92 ± 0.23 g (mean ± s.e.). Histological analysis showed that HGPIN was present in about 35% Castration and prostate cancer in TRAMP mice AV Bono et al and ADC in 7% of the prostate area ( Figure 1A ). HGPIN is composed of dysplastic columnar epithelial cells, with hyperchromatic nuclei, a few secretory vacuoles and a reduced nucleus-cytoplasm ratio. They pack together, lose normal polarization and form randomly stratified papillae that project into the lumen and occasionally merge to create pseudolumina ( Figure 1B , a-d). ADC tumour cells are arranged in abnormal glands or multiple papillae with vessel-rich stromal axes ( Figure 1B , e-l).
Where differentiation is less pronounced, the tendency to form gland-like structures is lost, and the cells grow in strings or mats. The nucleus-cytoplasm ratio of ADC cells is even more reduced than that of HGPIN cells. They also display many more mitoses, often abnormal and close to necrotic cells. As shown in Figure 1A , the percentage of prostate gland affected by ADC increases from the 13th to 30th week of age. At the 20th week, a small PDC focus was detected histologically in only one mouse (Figure 2a) . It was neither palpable in vivo nor evident macroscopically. From the 25th week, abdominal palpation revealed a mass about 0.3-0.5 cm in diameter ascribable to PDC in 5 of 10 mice and confirmed macroscopically and histologically after the killing at 30 weeks (group E). At that time, in PDC large masses (3.2±2.5 cm 3 , mean±s.d.), scanty remnants of HGPIN and ADC were still visible. Typically, the ADC component and the PDC component were juxtaposed without tumour-type transition zones. As in human small-cell prostate carcinoma, PDC tumours are composed of diffusely growing small cells with a low nucleuscytoplasm ratio. Mitotic figures are extremely numerous and often aberrant (Figure 2b ). Apoptotic figures and necrotic microfoci are also very frequent. The larger tumours displayed many extensive haemorrhagic necrosis foci. Staining for SV40Tag disclosed alternation of positive and weakly stained (or in a few cases unstained) areas. Intense BrdU and PCNA positivity indicated that, leaving aside the presence of the transgene, these cells are able to proliferate quickly (Figures 2c and d) . The similarity of PDC with the human form was confirmed by positivity for synaptophysin and almost total negativity for cytokeratins [22] [23] [24] (Figure 2e ).
Effects of castration on TRAMP prostrate carcinogenesis
The effect of surgical castration on the structure and development of neoplastic lesions in the TRAMP mouse prostate was evaluated by operating mice at 13 weeks of age, when HGPIN and foci of ADC are already present, and by comparing the pathological features of the prostate of castrated and non-castrated mice at 20 and 30 weeks of age. Because PDC is an aggressive tumour that grows rapidly and forms solid and voluminous masses that overwhelms the development of HGPIN and Castration and prostate cancer in TRAMP mice AV Bono et al ADC, the PDC data will be illustrated separately. In animals without PDC, the mean GU apparatus weight at both 20 and 30 weeks of age was much smaller than that of the non-castrated animals (Po0.0001), and even lower than that of 13-week-old non-castrated mice (P ¼ 0.01) (Figure 3a ). These weights, in fact, were 0.34 ± 0.6 g for the mice in group B (vs 1.26±0.32 g for group D) and 0.32 ± 0.04 g for the mice in group C (vs 2.8 ± 0.92 g for the mice in group E), whereas the prostate area was 0.9 ± 0. Immunohistochemistry revealed striking differences (Po0.0001) between castrated and non-castrated mice at both 20 and 30 weeks ( Table 2 ). The percentage of nuclei positive for SV40Tag, which is the transforming transgene; PCNA, a marker of proliferating cells; BrdU, marking cells that took up BrdU, that is, were dividing and synthesizing their DNA during the 2 h of BrdU administration, and AR was evaluated in the normal and tumoral prostate. The majority of the prostate epithelial cells in control animals at any age were positive for SV40Tag, PCNA, BrdU and AR, whereas only a few or no cells were positive in castrated mice (Figures 4c and d  and 5a and b) . It is noteworthy that according to the absence of SV40Tag and proliferation marker-positive cells in prostate epithelial and stromal compartments, HGPIN and ADC were not present in castrated mice at both 20 and 30 weeks of age.
By contrast, the occurrence and growth of PDC were unaffected by castration. PDC was detected in 2 and 5 out of 10 mice at the 20th (group B) and 30th (group C) week, respectively. PDC volumes, too, evaluated at 30 weeks of age, were comparable in castrated and non- Castration and prostate cancer in TRAMP mice AV Bono et al castrated mice (4.1 ± 2.96 group C vs 3.2 ± 2.5 cm 3 group E, mean±s.d., P ¼ 0.6). No significant macroscopic nor histopathological differences between PDCs in the castrated animals and the controls were detected. Interestingly, in PDC tumours, the percentage of SV40Tag-, BrdU-and PCNA-positive nuclei was also high in the castrated animals ( Table 2 ). Positivity was irregular in both groups of PDC in terms of distribution and intensity. AR expression was hardly detectable in control and in castrated PDC tumours (Figures 5c and d) .
Metastases from ADC were never observed. All the metastases detected displayed the histological features of PDC and were developed in mice with PDC. No distant metastases were observed in lungs and lymph nodes at 20 weeks. At 30 weeks, macroscopic and microscopic analyses showed that SV40Tag-positive lymph node metastases were present in 2/5 controls compared with 4/5 castrated animals. Micrometastases, composed of 4-10 highly SV40Tag-positive cells (Figure 5e ), were detected in the lungs of 3/5 PDC mice in the control group E and 2/5 in the castrated group C. Liver metastases due to PDC were noted at the 30th week in one control mouse with no other metastases. Lung, lymph node, liver (Figure 5f ) and renal metastases were noted in one castrated mouse.
Discussion
This study assesses the role of androgen ablation by surgical castration in the development of carcinoma of the prostate in TRAMP mice, all of which display HGPIN in the 6th to 7th week of life that then progresses to ADC.
The majority of the epithelial cells in these lesions, such as the columnar luminal cells that coat the normal prostate, express AR. Mice with HGPIN and ADC may live for a long time and usually die as a result of blockage and dilatation of the urinary tract with hydronephrosis. In about 45-50%, however, a PDC similar to the human small-cell prostate carcinoma stochastically arises between the 18th and the 25th week. It overwhelms and replaces both HGPIN and ADC, and is rapidly fatal. Here, the expression of androgen receptors is almost undetectable. Castration at the 13th week results in the regression of HGPIN and ADC foci and renders the prostate hypotrophic. It also reduces proliferation of the epithelial cells and blocks their differentiation. The prostate of castrated mice, in fact, displays hypoplastic glands coated with flat cells very similar to the basal flatcubic cells present in the normal prostate. HGPIN and ADC in TRAMP mice were found to be extremely androgen-dependent. Deprivation of androgens, in fact, cures HGPIN and ADC and prevents their further occurrence and growth. This indicates that the androgen pathway is a suitable therapeutic target.
Castration does not appear to have any effect on the development of PDC. Several authors have reported that castration inhibits HGPIN and ADC growth and favours the development of PDC. [25] [26] [27] Our results do not confirm the favouring action of androgen depletion on the occurrence of PDC, as the absolute number of PDC in castrated and control mice was identical.
In TRAMP mice, the SV40 transgene under the probasin promoter should only be expressed in epithelial cells in which the androgen pathway is active. 14, 15 Explanation of the development of HGPIN and ADC Castration and prostate cancer in TRAMP mice AV Bono et al due to expression of the oncogene is thus intuitive. The prostate glands are usually carpeted with differentiated secretory luminal cells. In TRAMP mice, part of these androgen receptor-positive cells express the transgene as early as the 6th to 7th week of life. Transformation resulting in HGPIN and ADC may be supposed to begin in these cells, whose enhanced proliferation rate, induced by the transgene, leads to an excess of well or moderately differentiated epithelial cells. In castrated mice, these androgen-dependent cells, even if SV40-positive, undergo apoptosis and disappear. The way in which PDC, without immunohistochemically detectable AR, begins and grows in TRAMP mice is less certain. As the growth and proliferation of PDC are not influenced by castration, it is highly likely that the PDC-initiating cells in castrated mice express an AR that is functionally independent of the actual presence of androgens and therefore able to prime the SV40 transgene promoter in castrated animals, too. This situation may reflect the occurrence of many polymorphisms or mutations in androgen receptors or along the androgen pathway 28 and explain the fact that their immunohistochemistry is negative on PDC tumours in both control and castrated animals. 29, 30 Recent papers focus attention on the prostate TAP (transient-amplifying population), a more rapidly cycling cell type derived from slowly proliferating stem cells thought to be contained in the epithelial basal compartment. 31 These TAP cells express the AR mRNA and are responsive to androgen action, although they are androgen independent for survival. In contrast, their terminally differentiated progeny, the secretory luminal cells, require the presence of androgen for survival. Our findings suggest that if SV40Tag is expressed by TAP cells, possibly in response to androgen signalling due to a mutation along the androgen pathway, a PDC tumour will form, independent of the presence of testicular androgens. Another explanation of SV40 expression under the probasin promoter on part of cells that do not express AR may be provided by the recent identification of proteins, such as a Foxa2, which could activate androgen-dependent, prostate-specific genes in an androgen receptor and ligand-independent manner. 32 These proteins are expressed in a small proportion of basal epithelial cells of the adult human and mouse prostate that coexpress synaptophysin, a marker for neuroendocrine differentiation, and would thus be able to express SV40Tag both in normal and castrated mice and give rise to small-cell tumours with neuroendocrine differentiation.
32,33 HGPIN-and ADC-initiating cells may therefore be expected to be different from PDC-initiating cells, as suggested by several observations: (1) two epithelial prostate tumours with a different histotype develop in TRAMP mice at different ages: ADC is derived from the HGPIN and is composed of differentiated luminal cells and PDC arises from poorly differentiated cells similar to basal cells and predominates on HGPIN and ADC; (2) there are no histological signs of progression from HGPIN or ADC to PDC; (3) it has been possible to obtain tumour lines from PDC, but not from HGPIN and ADC; (4) these lines, when transplanted in syngeneic mice, do not give rise to tumours with aspects of luminar differentiation; (5) if HGPIN and ADC do not develop or regress (as after surgical castration), PDC tumours develop with the same features.
The development of prostate carcinoma in TRAMP mice resembles the human pattern in the development of HGPIN and ADC, but is different with regard to PDC in that this is not a progression of ADC, but an independent tumour comparable with human small-cell prostate carcinoma, whose morphological and growth features and aggressiveness are exactly the same as those of PDC in TRAMP mice. It has been reported that castration of TRAMP mice favours the development of androgenindependent prostate carcinomas and this circumstance has been likened to the human setting. Castration or the use of antiandrogens is followed by the development of a more aggressive androgen-independent tumour in about 85% of patients. Our experiments, although conducted on a few animals, do not confirm this kind of progression in TRAMP mice. PDC, in fact, was similar in morphology, aggressiveness, age at development and number in both the castrated and the non-castrated mice. This finding, when read in conjunction with more recent data, 34 supports the view that PDC in TRAMP mice is not favoured by a selective pressure due to androgen deprivation. Castration and prostate cancer in TRAMP mice AV Bono et al
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